Back to Journals » International Journal of General Medicine » Volume 13
The Effect of Hemodialysis on Axial Length, Ocular Surface, and Intraocular Pressure in Patients with End-Stage Renal Failure
Authors Kalayci M, Hassan IA, Keinan IA, Cetinkaya E, Suren E, Tahtabasi M, Sumbul HE
Received 11 September 2020
Accepted for publication 30 October 2020
Published 6 November 2020 Volume 2020:13 Pages 1035—1042
DOI https://doi.org/10.2147/IJGM.S281546
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Scott Fraser
Mustafa Kalayci,1,2 Ibrahim Ali Hassan,1 Ibrahim Abdi Keinan,1 Ersan Cetinkaya,2 Elcin Suren,2 Mehmet Tahtabasi,3 Hilmi Erdem Sumbul4
1Department of Ophthalmology, Somalia Mogadishu-Turkey Education and Research Hospital, Mogadishu, Somalia; 2Department of Ophthalmology, Antalya Training and Research Hospital, Antalya, Turkey; 3Department of Radiology, Somalia Mogadishu - Turkey Education and Research Hospital, Mogadishu, Somalia; 4Department of Internal Medicine, Somalia Mogadishu-Turkey Education and Research Hospital, Mogadishu, Somalia
Correspondence: Mustafa Kalayci Antalya Egitim ve Arastirma Hastanesi, Goz Poliklinigi, Konyaalti, Antalya, Turkey
Tel +90 5327280963
Email drkalayci07@hotmail.com
Purpose: To evaluate the changes in intraocular pressure (IOP), central corneal thickness (CCT), axial length, and ocular surface in patients with end-stage renal failure after single-session hemodialysis treatment and to examine the correlation of these findings with systemic hemodynamic parameters.
Patients and Methods: A total of 112 eyes of 112 patients enrolled in a hemodialysis treatment program for three times a week (approximately four hours per session) for at least three months in our hospital between December 2019 and March 2020 were included in the study. Approximately 30 minutes before and after hemodialysis, the best-corrected visual acuity measurement, slit-lamp examination, IOP measurement, and dilated fundus examination with the Goldmann applanation tonometer were performed in all patients. The axial length measurement was undertaken by ultrasonic biometry, and the CCT measurement by ultrasonic pachymetry. The ocular surface evaluation was performed based on the tear breakup time (BUT), basal secretion time (BST) and keratoepitheliopathy score. Blood pressure, serum osmolarity, and body weight were measured before and after hemodialysis.
Results: The mean IOP decreased from 12.2 ± 3.5 to 10.8 ± 2.2 mmHg, and the mean decrease was 1.4 ± 2 mmHg, indicating statistical significance (p< 0.001). The mean CCT dropped from 502 ± 41.2 to 494.1 ± 35.4 μm, and the mean decrease was 8.1 ± 7.7 μm, which also indicated a statistically significant change (p< 0.001). The mean axial length was reduced from 23.1 ± 0.8 to 22.9 ± 0.8 mm. The reduction in the axial length was significant with an average value of 0.26 ± 0.15 mm (p< 0.001). When the ocular surface changes were examined, BUT decreased from 7.4 ± 3.1 to 6.3 ± 2.5 s, BST from 8.6 ± 1.7 to 6.6 ± 1.3 mm, and the keratoepitheliopathy score increased from 0.36 ± 0.61 to 1.59 ± 0.93, and all these changes were statistically significant (p< 0.001). There was a significant correlation between the axial length change and the IOP change (r=0.202, p=0.03). A significant correlation was also observed between BST and plasma colloid osmotic pressure (r=− 0.268, p=0.004). In addition, there was a strong correlation between serum osmolarity and the keratoepitheliopathy score (r=− 0.437, p< 0.001).
Conclusion: Hemodialysis causes significant changes in IOP, CCT, axial length, and ocular surface. These changes should be considered in the ophthalmological examination of patients after the hemodialysis session.
Keywords: end-stage renal failure, hemodialysis, axial length, intraocular pressure, Africa
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.